Repair of cartilage defects in osteoarthritis rats with induced pluripotent stem cell derived chondrocytes

Zhu, Yanxia; Wu, Xiaomin; Liang, Yuhong; Gu, Heng; Song, Kedong; Zou, Xuenong; Zhou, Guangqian

doi:10.1186/s12896-016-0306-5

Cited by 58 publications

(50 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Avoiding cartilage hypertrophy is a key challenge when repairing articular cartilage. However, the evaluation of cartilage hypertrophy was often ignored in cartilage tissue engineering [27][28][29]. COL X is a short-chain collagen expressed by hypertrophic chondrocytes during endochondral ossification and often used as a classic marker of hypertrophic chondrocytes.…”

Section: Discussionmentioning

confidence: 99%

A lithium-containing biomaterial promotes chondrogenic differentiation of induced pluripotent stem cells with reducing hypertrophy

Chen

Gao

et al. 2020

Stem Cell Res Ther

View full text Add to dashboard Cite

Background: Induced pluripotent stem cells (iPSCs) exhibit limitless pluripotent plasticity and proliferation capability to provide an abundant cell source for tissue regenerative medicine. Thus, inducing iPSCs toward a specific differentiation direction is an important scientific question. Traditionally, iPSCs have been induced to chondrocytes with the help of some small molecules within 21-36 days. To speed up the differentiation of iPSCs, we supposed to utilize bioactive ceramics to assist chondrogenic-induction process. Methods: In this study, we applied ionic products (3.125~12.5 mg/mL) of the lithium-containing bioceramic (Li 2 Ca 4 Si 4 O 13 , L2C4S4) and individual Li + (5.78~23.73 mg/L) in the direct chondrogenic differentiation of human iPSCs. Results: Compared to pure chondrogenic medium and extracts of tricalcium phosphate (TCP), the extracts of L2C4S4 at a certain concentration range (3.125~12.5 mg/mL) significantly enhanced chondrogenic proteins Type II Collagen (COL II)/Aggrecan/ SRY-Box 9 (SOX9) synthesis and reduced hypertrophic protein type X collagen (COL X)/matrix metallopeptidase 13 (MMP13) production in iPSCs-derived chondrocytes within 14 days, suggesting that these newly generated chondrocytes exhibited favorable chondrocytes characteristics and maintained a low-hypertrophy state. Further studies demonstrated that the individual Li + ions at the concentration range of 5.78~23.73 mg/L also accelerated the chondrogenic differentiation of iPSCs, indicating that Li + ions played a pivotal role in chondrogenic differentiation process.Conclusions: These findings indicated that lithium-containing bioceramic with bioactive specific ionic components may be used for a promising platform for inducing iPSCs toward chondrogenic differentiation and cartilage regeneration.

show abstract

Section: Discussionmentioning

confidence: 99%

A lithium-containing biomaterial promotes chondrogenic differentiation of induced pluripotent stem cells with reducing hypertrophy

Chen

Gao

et al. 2020

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…Induced pluripotent stem cells (iPSCs) are also becoming a promising cell source for stem cell-based therapy [72]. They are a kind of stem cells established in the laboratory that can be reprogrammed into somatic cells.…”

Section: Induced Pluripotent Stem Cellmentioning

confidence: 99%

Current perspectives in stem cell therapies for osteoarthritis of the knee

Kim

2020

Yeungnam Univ J Med

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are emerging as an attractive option for osteoarthritis (OA) of the knee joint, due to their marked disease-modifying ability and chondrogenic potential. MSCs can be isolated from various organ tissues, such as bone marrow, adipose tissue, synovium, umbilical cord blood, and articular cartilage with similar phenotypic characteristics but different proliferation and differentiation potentials. They can be differentiated into a variety of connective tissues such as bone, adipose tissue, cartilage, intervertebral discs, ligaments, and muscles. Although several studies have reported on the clinical efficacy of MSCs in knee OA, the results lack consistency. Furthermore, there is no consensus regarding the proper cell dosage and application method to achieve the optimal effect of stem cells. Therefore, the purpose of this study is to review the characteristics of various type of stem cells in knee OA, especially MSCs. Moreover, we summarize the clinical issues faced during the application of MSCs.

show abstract

“…Induced pluripotent stem cells (iPSCs) are adult cells that have been reprogrammed using embryonic transcription factors to become pluripotent . Like ASCs, iPSCs circumvent the ethical issues of embryonic stem cells (ESCs), and their pluripotency makes them a promising candidate for cartilage and bone repair . The first human clinical trials using iPSCs are currently underway to treat macular degeneration .…”

Section: Stem Cell Therapy Bone Marrow Concentrate Lipoaspirate Anmentioning

confidence: 99%

“…118 Like ASCs, iPSCs circumvent the ethical issues of embryonic stem cells (ESCs), and their pluripotency makes them a promising candidate for cartilage and bone repair. [119][120][121][122] The first human clinical trials using iPSCs are currently underway to treat macular degeneration. 123 Moreover, iPSCs are the focus of research for other conditions, such as Alzheimer's, 124 Parkinson's, 125 and cardiovascular disease.…”

Section: Sources Of Stem Cells and Their Therapeutic Potentialmentioning

confidence: 99%

Current perspectives on biological approaches for osteoarthritis

Whitney

Liebowitz

Bolia

et al. 2017

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Musculoskeletal injuries that disrupt the structure and function of diarthrodial joints can cause permanent biomechanical alterations and lead to a more severe, chronic condition. Despite advancements that have been made to restore tissue function and delay the need for joint replacement, there are currently no disease-modifying therapies for osteoarthritis (OA). To reduce the risk of OA, innovative preventive medicine approaches have been developed over the last decade to treat the underlying pathology. Several biological approaches are promising treatment modalities for various stages of OA owing to their minimally invasive nature and actively dynamic physiological mechanisms that attenuate tissue degradation and inflammatory responses. Individualized growth factor and cytokine therapies, tissue-engineered biomaterials, and cell-based therapies have revolutionary potential for orthopedic applications; however, the paucity of standardization and categorization of biological components and their counterparts has made it difficult to determine their clinical and biological efficacy. Cell-based therapies and tissue-engineered biologics have become lucrative in sports medicine and orthopedics; nonetheless, there is a continued effort to produce a biological treatment modality tailored to target intra-articular structures that recapitulates tissue function. Advanced development of these biological treatment modalities will potentially optimize tissue healing, regeneration, and joint preservation strategies. Therefore, the purpose of this paper is to review current concepts on several biological treatment approaches for OA.

show abstract

Repair of cartilage defects in osteoarthritis rats with induced pluripotent stem cell derived chondrocytes

Cited by 58 publications

References 41 publications

A lithium-containing biomaterial promotes chondrogenic differentiation of induced pluripotent stem cells with reducing hypertrophy

A lithium-containing biomaterial promotes chondrogenic differentiation of induced pluripotent stem cells with reducing hypertrophy

Current perspectives in stem cell therapies for osteoarthritis of the knee

Current perspectives on biological approaches for osteoarthritis

Contact Info

Product

Resources

About